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lipid nanoparticles using B16F10 melanoma cell
lines
Vikram S Shenoy1*, Rajiv P Gude2 and Rayasa S Ramachandra Murthy1Abstract
The present study is aimed to investigate the formulation and in vitro anticancer activities of solid lipid nanoparticles
(SLNs) of 5-fluorouracil (5-FU) prepared using glyceryl monostearate (GMS) and cetyl palmitate (CP) by hot
homogenization method. The lipids were selected based on the partition coefficient of 5-FU in lipids. The lipid
nanoparticles were optimized for process and formulation parameters. The optimized nanoparticles were characterized
for their zeta potential, morphology, release kinetics, and anticancer activity. Higher entrapments were achieved using a
combination of emulsifiers. The zeta potential of the optimized CP and GMS SLN formulation were −8.26 and −9.35 mV,
respectively. Both the optimized formulations were spherical. The in vitro release studies of SLNs of both the lipid carriers
followed Peppas-Korsenmeyer equation when carried out at pH 3.5 and 7.4. The chemosensitivity assay carried out in
B16F10 cell lines revealed that CP SLNs had better cytotoxicity than 5-FU solution and GMS SLNs at 48 h of incubation.
Subtoxic concentration of 5-FU-loaded CP SLNs (0.12 μg/mL) possessed comparable antimigrational activity, colony
inhibition activity, and cytopathic as that of 5-FU solution effects. The results indicated that encapsulating 5-FU in CP
would be a promising delivery system for delivering 5-FU.
Keywords: Cell morphology, Cetyl palmitate, Chemosensitivity assay, Colony formation, Glyceryl monostearate,
Hot homogenizationBackground
5-Fluorouracil (5-FU) is one of the oldest chemotherapeu-
tic drugs, and it has been used commonly against colon,
stomach, breast, and pancreatic cancers [1,2]. It is a fluori-
nated analog of pyrimidine base uracil, which is metabo-
lized intracellularly to its active form, fluorodeoxyuridine
monophophate. The active form inhibits DNA synthesis by
inhibiting the normal production of thymidine. 5-FU is an
S-phase-active anticancer agent, and it has no activity
when cells are in G0 or G1 [3]. It is sparingly soluble in
water [4]. On intravenous administration, it causes severe
toxic effects of gastrointestinal, hematological, neural, car-
diac, and dermatological origin [5]. The bioavailability of 5-
FU is greatly limited by rapid catabolism in the blood, liver,
and other organs. After IV injection in humans, the drug
has a half-life in blood of only 8 to 20 min [6]. Therefore,* Correspondence: vikramsshenoy@gmail.com
1Department Pharmacy, M S University of Baroda, Fatehgunj, Vadodara,
Gujarat 390 002, India
Full list of author information is available at the end of the article
© 2013 Shenoy et al.; licensee Springer. This is
Attribution License (http://creativecommons.or
in any medium, provided the original work is p5-FU requires an effective delivery system for appropriate
therapy. Solid lipid nanoparticles (SLNs) have emerged as a
promising delivery system for delivery of anticancer drugs.
SLNs combine the advantages of polymeric nanoparticles,
fat emulsions, and liposomes. In addition, they also avoid
some of their disadvantages. Solid matrices in SLNs pro-
vide controlled release of drugs, thereby avoiding the burst
release generally associated with fat emulsions. Hot
homogenization method is one of the methods for the
preparation of SLN that is found appropriate for produc-
tion scale [7].
Encapsulating 5-FU in SLN formulations has been
attempted by a few researchers previously. Mao et al. inves-
tigated formulation factors influencing the properties of 5-
FU-loaded SLNs prepared by hot homogenization method
[8]. 5-FU SLNs prepared using phospholipids were found
to effectively reduce MDA-MB-468 tumor growth [9]. As
an inhalation therapy, 5-FU SLNs have been found effective
in lung cancer [10,11]. Multiple emulsion-ultrasonication
method has also been employed to prepare 5-FU, whichan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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targeting therapeutic agents for curing primary lung carcin-
oma [12]. In a recent report, 5-FU SLNs were formulated
using Dynasan as lipid matrix to treat colon cancer [13].
In the present study, SLNs of 5-FU were prepared by
hot homogenization method. Cetyl palmitostearate (CP)
and glyceryl monostearate (GMS) were selected as lipid
carriers based on the partitioning of 5-FU in various
lipids. The process variables such as speed of stirrer
(ULTRA-TURRAX, IKA, Rawang, Selangor, Malaysia),
homogenization pressure, and homogenization cycles
were optimized. The stability of the optimized SLNs was
assessed by electroflocculation method. The morphology
of SLNs was studied using a transmission electron
microscope (TEM). The in vitro studies carried out on
the prepared SLNs included the release studies in pH 3.5
and 7.4. The SLNs were also assessed for its anticancer
activity using metastatic B16F10 melanoma cell lines
through functional assays such as chemosensitive assay,




5-FU was a gift sample received from M.S. Otto Kemi
(Mumbai, India), and glyceryl monostearate, cetyl palmitate,
sodium taurocholate (STC), and poloxamer 407 (P407)
were gifts provided by Colorcon India Ltd. (Mumbai, India).
All other chemicals and reagents used were of laboratory
grade and used as such.
The apparatus that were used in this study are
the following: spectrophotometer (Shimadzu UV 1601,
Shimadzu Corporation, Kyoto, Japan), high-shear apparatus
(ULTRA-TURRAX T18, IKA, Rawang, Selangor, Malaysia),
high-pressure homogenizer (Emulsiflex E5, AVESTIN,
Inc., Ottawa, Ontario, Canada),particle size analyzer
(Malvern Hydro 2000SM particle size analyzer, Malvern In-
struments, Worcestershire, UK), zeta potential analyzer
(Malvern Zetasizer, Nano ZS90, Malvern Instruments,
Worcestershire, UK); TEM apparatus (Zeiss TEM 109, Carl
Zeiss, Inc., Oberkochen, Germany), TEM size-measuring
device (ultrastructuresize calculator (Pello scale), Van
Loenen Instruments, Zaandam, The Netherlands), MTT
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide] test apparatus (Spectramax 190 microplate spectrom-
eter, Sunnyvale, CA, USA),wound width-measuring
apparatus (laser capture microdissection microscope with
PalmRobo software, Carl Zeiss, Inc., Oberkochen, Germany,
and Leighton tube apparatus (inverted-light microscope,
Shamboo Scientific Glass Works, Haryana, India).
Cell and culture conditions
B16F10, a highly metastatic lung selected subline derived
from C57/BL6 murine melanoma, was purchased fromNational Center for Cell Science (Pune, India). The cell
line was maintained as a continuous culture in Iscove’s
minimum Dulbecco’s medium (IMDM;Gibco-BRL,
Gaithersburgh, MD, USA), supplemented with 10% fetal
bovine serum (FBS; Himedia, Mumbai, India), 100 U/mL
penicillin, and 100 μg/mL streptomycin. Cells were
grown in a humidified atmosphere of 5% CO2 and 95%
air at 37°C. Media were replenished every three days.
Partitioning behavior of 5-FU in various lipids
Ten milligrams of 5-FU was dispersed in a mixture of
melted lipid (1 g) and 1 mL of hot distilled water and
shaken for 30 min in a hot water bath. Aqueous phase was
separated after cooling and analyzed spectrophotometric-
ally at λmax 267.
Preparation of solid lipid nanoparticles
SLNs were prepared by modified hot homogenization
method. Briefly, CP and GMS were dissolved in ethanol
and added to a hot P407/P407-to-STC solution (5°C above
the melting point of the lipid) using the high-shear appar-
atus. The resultant dispersion was then passed through
the high-pressure homogenizer at 65°C for 3 cycles.
Particle size analysis
The particle size was measured in a particle size
analyzer. The SLN dispersion was added to the sample
dispersion unit containing stirrer and stirred in order to
minimize the interparticle interactions. The obscuration
range was maintained between 5% and 20%. The instru-
ment was set to measure the sample three times at a rate
of 3,000 snaps (or counts) per second, and the average
volume mean diameter was obtained.
Percent entrapment efficiency
The prepared SLNs were passed through a column of
sephadex G25. The in-house sephadex G25 column had a
dimension of 1.5 cm × 4 cm. Initially, a blank check was
carried out on a 1-mL column and was saturated. Lipid
nanoparticle suspensions of 0.2, 0.3, 0.5, and 1 mL were
loaded in column with water elution. The flow rate was
found to be 1.0 mL/min−1. It was possible to separate en-
capsulated and free drug from 0.2 mL of sample (column
recovery, 99.26; RSD, 1.54%). An aliquot of 5 mL of this
formulation was used for analysis. The SLNs were shaken
with 5 mL of chloroform in a separating funnel. The
chloroform portion was separated and analyzed for 5-FU
content spectrometrically at λmax 267 nm against chloro-
form as reference.
Zeta potential
Zeta potential of nanoparticles was measured using the
zeta potential analyzer. The nanoparticles were dispersed
in water, and the zeta potential was determined.
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TEM was performed to measure the morphology and
size distribution of nanoparticles. The apparatus was op-
erated at an acceleration voltage of 60 kV. To measure
the morphology and size distribution of nanoparticles, a
drop of sample solution was placed onto a 300-mesh
copper grid coated with carbon. Approximately 2 min
after deposition, the grid was tapped with filter paper to
remove surface water and was air-dried. Negative stain-
ing was performed using a droplet of 2 wt.% aqueous ur-
anyl acetate. The size of the nanoparticles was measured
using the ultrastructure size calculator (Pello scale).
In vitro release studies
The in vitro release of 5-FU-loaded CP/GMS SLNs was
evaluated by diffusion technique. Dialysis bags with a mo-
lecular weight cutoff of 12,000 (Himedia, Mumbai, India)
were used in the study. Before performing the in vitro re-
lease, the dialysis bag was tested for permeation study of
the drug. One milliliter of SLN dispersion was loaded in
the dialysis tube, and the dialysis tube tied firmly at both
ends was immersed in 50 mL phosphate-buffered saline
(PBS) (pH 3.5 and 7.4). Aliquots of 5-mL samples were
withdrawn from the medium and replaced with the same
volume of fresh dissolution medium every time. The sam-
ples were estimated spectrophotometrically at λmax 268.
In vitro anticancer studies
Chemosensitivity assay
The cytotoxicity of 5-FU and its CP/GMS SLNs were
evaluated by MTT method. The experiment was carried
out as follows: 100 μL of cell culture medium (IMDM
supplemented with 10% FBS and antibiotics) containing
4 × 104 cells was added in each well in a 96-well plate
and incubated for 48 h. The confluent wells were treated
with 5-FU drug solution and 5-FU-loaded CP/GMS SLN
concentrations prepared in culture media between 10°
and 5 × 101 μg/mL. The empty nanoparticles of similar
dilutions were added to the control wells.
After 48 h of incubation (in moisture atmosphere,
enriched by 5% CO2), the plates were washed with PBS.
An aliquot of 100 μL of culture medium containing 20 μL
MTT was added to the plates and incubated for further
4 h at 37°C. After this, the contents of the plates were re-
placed with 50 μL DMSO, and optical density at 540 nm
was measured after background correction at 690 nm
using the Spectramax 190 microplate spectrometer.
Wound assay
B16F10 cells were plated in 35-mm petriplates and were
allowed to grow to 60% confluency. The plates were
treated with subtoxic doses of 5-FU solution, 5-FU-loaded
CP/GMS SLNs, and their corresponding blanks (for 24
and 48 h). At the end of incubation, the cells were washedwith PBS, and the wound was prepared on the monolayer.
A zero time point wound was kept as reference plate.
Remaining plates were incubated for 24 and 48 h in the
presence of serum-free IMDM. The plates were fixed with
methanol and stained with crystal violet (Sigma-Aldrich,
St. Louis, MO, USA). The wound widths were measured
using the laser capture microdissection microscope using
PalmRobo software after 24 and 48 h of incubation. The
width of the wound was calculated for each dose on







Twenty-five wound readings of each formulation were
taken. The experiment was performed in duplicate. Per-
cent relative wound widths were calculated, and the stat-
istical significance in the case of relative wound widths
were calculated using SPSS package.
Colony formation
B16F10 melanoma cells were incubated for 24 h (4 ×
103cells per plate) and 48 h (2 × 103 cells per plate). The
plates were then treated with subtoxic concentrations of
5-FU solution, 5-FU-loaded CP/GMS SLNs, and their cor-
responding blanks. After incubation, the plates were
washed with PBS and then incubated with complete
medium (10% FBS and IMDM) for another 48 h. The cells
were then fixed using 70% alcohol and stained using the
crystal violet. Colonies having more than 50 cells were
counted, and the percent colony inhibition (PCI) capacity
of the formulations was calculated as follows:
PCI ¼
Numberof colonies inUC untreatedcontrolð Þ




B16F10 melanoma cells were grown on cover slips in
30-mm petriplates in the presence of complete medium
(10% FBS with IMDM). The plates were treated with sub-
toxic concentrations of 5-FU solution, 5-FU-loaded CP/
GMS SLNs, and their corresponding blanks and incubated
for 24 and 48 h. After incubation, the cells are fixed using
70% alcohol and then stained using hematoxylin and
counter stained with eosine. The cover slips were washed
in xylene and finally mounted on the slides. The changes
in morphology of B16F10 cells after the treatments of
5-FU solution, 5-FU-loaded CP/GMS SLNs, and their cor-
responding blanks were assessed under the inverted-light
microscope.
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Preparation and optimization of SLNs
Drug partitioning between various lipids and water has
been used by several researchers to select appropriate
lipids in the preparation of lipid nanoparticles [14,15]. The
lipids used in the study and the partition coefficients of
5-FU in these lipids are provided in Table 1. The partition
coefficient of 5-FU in CP and GMS was high, and there-
fore, these lipids were selected for further studies.
Influence of process parameters
Initially, the influence of process parameters such as
speed of stirrer (ULTRA-TURRAX), homogenization
pressure, and homogenization cycles were investigated.
The investigation was carried out using blank SLNs
using 4% lipid (CP/GMS) and 1% P407 as emulsifier.
The influence of stirring speedsof ULTRA-TURRAX on
SLNs was studied and found to be 6,500 and 9,500 rpm
at time durations of 5, 10, and 15 min. The stirring
speed of 9,500 rpm for 15 min provided the maximum
mean particle size of SLNs (5 μm). Since no decrease in
mean particle size was observed on further increase of
the stirring speed and stirring time, 9,500 rpm for 15
min was used for preparing SLNs. Similarly, the effects
of homogenization cycles and homogenizer pressure
were evaluated by measuring the mean particle sizes at
5,000, 10,000, and 15,000 psi at 1, 2, and 3 cycles.
Homogenization speed of 5,000 psi pressure for 3 cycles
gave a mean particle size of 526 nm. At 15,000 psi for 3
cycles, maximum reduction in mean particle size was
observed, which was found to be 198 nm.
Effect of lipid and emulsifier concentrations
The lipid concentration and the emulsifier content are
known to influence the particle size and the drug load-
ing of the SLNs [14]. Lipid concentrations between 2%
and 4% were used in the optimization of SLNs. In the
optimization of both the lipid matrices (CP and GMS),
the percent entrapment efficiencies (EE%) increased with
the increase in lipid concentration from 2% to 4% and at
P407 concentration of 1%. In the case of CP SLNs, the
EE% increased from 49.65% to 69.46% (Table 2). WhileTable 1 Partition coefficients of 5-FU in various lipids
(n = 3)
Lipids 5-FU in water
(mg/mL)
Palmitic acid 5.24 ± 0.39
Stearic acid 4.65 ± 0.56
Glyceryl palmitostearate (ATO 5) 3.79 ± 0.74
Witepsol H35 3.57 ± 0.57
Glyceryl monosterate 2.99 ± 0.14
Cetyl palmitate 2.85 ± 0.22in the GMS SLNs, the increase was from 41.82% to
60.27%. Increase in lipid content beyond 4% resulted in
agglomeration of SLNs.
Formulations with varying concentrations of 5-FU from
40 to 120 mg were used in optimizing 5-FU concentration.
Increase in drug concentration brought about an increase
in EE% in both the SLN formulations. The increase was
observed till 120 mg beyond which no increase in EE%
was observed. The increases in CP and GMS SLNs were
84.26 and 72.68, respectively.
STC and P407 were used in the optimization which
were incorporated individually or in combination. The
EE% was less when STC was used in comparison with
P407. When used in combination, the increase in STC
composition resulted in the decrease in EE%. In the CP
SLNs, the EE% increased from 72.62% to 86.94% when
the STC/P407 ratio was increased from 1:1 to 1:2. How-
ever, further increase in STC content did not increase
the EE% of 5-FU. A similar phenomenon was observed
with GMS SLNs; however, higher EE% was achieved with
STC/P407 (1:3). The percent drug loading of 5-FU in CP
and GMS SLNs were found to be 2.608% and 2.358%. A
previous study using phospholipids has also observed a
loading of 3% when prepared by hot homogenization
method [8]. The lipid and emulsifier concentrations had
little effects on the mean particle size of the SLNs.
The formulation parameters did not affect the particle
size of both the SLN formulations. It ranged from 153 to
208 nm in the case of GMS SLNs and 168 to 193 nm in
the case of CP SLNs. The zeta potential of the optimized
CP and GMS SLN formulation was found to be −8.26
and −9.35 mV, respectively.
Transmission electron microscopy
The 5-FU-loaded SLNs prepared from CP and GMS
were found to be of spherical shape. The mean particle
sizes were 150 and 200 nm (Figure 1a,b). Previously,
SLN preparations with CP and GMS have shown spher-
ical shape nanoparticles [15,16].
In vitro release studies
The release kinetics of 5-FU from the SLNs was assessed
at pH 3.5 and 7.4. The lipid carriers effectively retarded re-
lease of 5-FU in both media, although it was observed that
the release of 5-FU was faster in acidic medium (Figure 2).
The release pattern in both formulations showed burst re-
lease. The burst release was similar to what is observed
with SLNs commonly [13]. In pH 7.4, the release was
complete in 24 h, while it took only 16 h in pH 3.5. Burst
release of a drug generally takes place in lipid nanoparticles
that are obtained as a ‘drug-enriched shell with core shell
model.’ In these nanoparticles, the drug partitions to water
phase during production. The lipid precipitates on cooling,
and as a result of phase separation, the lipid forms a core
Table 2 Optimization of formulation parameters for 5-FU-loaded CP and GMS SLNs (n = 3)
Formulations 5-FU (mg) CP (mg) P407 (mg) STC (mg) EE (%) Particle size (nm)
Lipid content CP 1 40 2,000 1,000 - 49.65 ± 6.97 158 ± 16
CP 2 40 3,000 1,000 - 56.82 ± 5.3 176 ± 12
CP 3 40 4,000 1,000 - 69.46 ± 4.58 207 ± 10
Drug content CP 4 80 4,000 1,000 - 72.81 ± 3.86 175 ± 12
CP 5 120 4,000 1,000 - 84.26 ± 4.13 192 ± 11
CP 6 100 4,000 1,000 - 78.56 ± 2.98 205 ± 10
CP 7 140 4,000 1,000 - 80.38 ± 2.62 182 ± 11
P407 and STC ratio CP 8 120 4,000 500 500 72.62 ± 5.15 184 ± 11
CP 9 120 4,000 665 335 86.94 ± 4.24 198 ± 12
CP 10 120 4,000 750 250 78.56 ± 2.94 179 ± 13
CP11 120 4,000 - 1,000 57.28 ± 5.16 189 ± 12
Lipid content
GMS (mg) GMS 1 40 2,000 1,000 - 41.82 ± 7.75 165 ± 21
GMS 2 40 3,000 1,000 - 52.3 ± 8.31 172 ± 18
GMS 3 40 4,000 1,000 - 60.27 ± 4.58 168 ± 28
Drug content GMS 4 80 4,000 1,000 - 68.42 ± 3.56 182 ± 15
GMS 5 120 4,000 1,000 - 72.68 ± 2.93 191 ± 11
GMS 6 100 4,000 1,000 - 65.92 ± 3.8 177 ± 18
GMS 7 140 4,000 1,000 - 72.32 ± 3.42 182 ± 12
P407 and STC ratio GMS 8 120 4,000 500 500 66.82 ± 3.58 183 ± 15
GMS 9 120 4,000 665 335 73.37 ± 3.16 193 ± 12
GMS 10 120 4,000 750 250 78.56 ± 2.94 188 ± 14
GMS 11 120 4,000 - 1,000 60.15 ± 2.66 175 ± 17
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quid lipid phase and concentrates in the outer shell. The
drug partitioning into the aqueous phase increases with in-
crease in solubility in aqueous phase.
The release kinetics of drug from the carrier was
assessed using theoretical dissolution equations of zero-
order, first-order, Higuchi, and Peppas-Korsenmeyer kin-
etic models (Table 3). The release of 5-FU from both lipid
carriers in both media fitted into the Peppas-Korsenmeyer
model. The n in the Peppas-Korsenmeyer equation is indi-
cative of the mechanism of action. If the value of n isFigure 1 TEM photographs of (a) 5-FU-loaded CP and (b) 5-FU-loadedbelow 0.45, it denotes that the release follows Fickian class
I controlled drug release. If n has a value of 1, it indicates
a non-Fickian drug release. In the present study, the values
of n of both the nanoparticles CP and GMS were below
0.45 which means that the release from the nanoparticles
followed the Fickian class I release.
In vitro anticancer studies
Chemosensitivity assay
The free drug and SLN formulations demonstrated a
concentration-dependent antiproliferative activity (Figure 3).GMS SLNs.
Figure 2 Release profiles of 5-FU from CP and GMS SLNs at (a) pH 3.5 and (b) 7.4.
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completely inhibited the growth of B16F10 melanoma cells.
The SLN formulations showed better proliferative activity
compared to the drug solution (p < 0.05). Among the SLN
formulation, CP SLNs performed better than GMS SLNs
(p < 0.05). Previously, lipid nanoparticles of 5-FU has been
reported to effectively inhibit MDA-MB-468 breast cancer
cells [9]. The IC50 values of 5-FU solution, 5-FU-loaded CP,
and 5-FU-loaded GMS SLNs were found to be 0.24, 0.16,
and 0.52 μg/mL at 24 h. At 48 h, the IC50 values were 0.02,
0.02, and 0.04 μg/mL for 5-FU drug solution, 5-FU-loaded
CP SLN, and 5-FU-loaded GMS SLN, respectively. The
subtoxic concentrations for further studies were selectedTable 3 In vitro release kinetics of 5-FU-loaded CP/GMS SLNs
Kinetic models Zero order First order
r2 r2
CP nanoparticles pH 3.5 0.8571 0.6401
pH 7.4 0.8932 0.6624
GMS nanoparticles pH 3.5 0.9255 0.7415
pH 7.4 0.9346 0.7118based on these IC50 values which were 0.12, 0.08,
and 0.26 μg/mL for 5-FU, 5-FU-loaded CP SLNs, and
5-FU-loaded GMS SLNs, respectively at 24 h. At 48 h,
the subtoxic concentrations selected were 0.01, 0.01,
and 0.02 μg/mL, respectively, for 5-FU, 5-FU-loaded
CP SLNs, and 5-FU-loaded GMS SLNs.Wound assay
The in vitro analysis of migration of cells can be easily
carried out using wound assay [17]. Cell motility is an
important component of cell invasion and spread of can-
cer cells through the body. The ability to exploit factorsHiguchi Peppas-Korsenmeyer
r2 h−1 r2 n
0.9609 11.85 0.992 0.306
0.9793 9.87 0.9956 0.2948
0.9800 9.8177 0.9956 0.2947
0.9856 10.678 0.9941 0.2569
Figure 3 Percent cell viability of 5-FU-loaded CP and GMS SLNs compared to 5-FU solution at 48 h.
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greater ability to metastasize. 5-FU is known to inhibit cell
migration. In the study, 5-FU and its SLN formulations
were found to significantly exert antimigrational effect on
B16F10 cell lines at subtoxic concentrations compared to
the control (p > 0.5) (Figure 4a). At the end of 48 h, 5-FUFigure 4 Percent relative wound widths and photo samples of 5-FU-lo
loaded CP and GMS SLNs compared to 5-FU solution at 48 h; (b) photo sa
solution as well as their respective blank nanoparticles taken using the lasesolution (0.02 μg/mL) had better inhibitions compared
to the SLN formulations. Among the SLN formulations,
5-FU-loaded CP SLN (0.12 μg/mL) was found to have
comparable inhibition of cell motility of B16F10 with that
of 5-FU solution. As anticipated, the blank formulations
did not have any antimigrational activity. Photographicaded CP and GMS SLNs. (a) Percent relative wound widths of 5-FU-
mples of wound widths of 5-FU-loaded CP and GMS SLNs, 5-FU
r capture microdissection microscope.
Figure 5 Percent colony inhibition of 5-FU-loaded CP and GMS SLNs compared to 5-FU solution. At 24 and 48 h.
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ied is given in Figure 4b.
Evaluation of cell migration using scratch test carried
out on nanoparticulate formulation has been reported in
several studies. The method established titanium oxide
nanoparticles to be effective against tumor cells [18].
Lipid nanoparticles of opioids enhanced inhibition cap-
acities of opioids by twofold in comparison with CMS
nanotransporters when evaluated in HaCaT cells [19].Figure 6 Morphological changes after the treatment with 5-FU-loadeColony formation assay
In the study, the subtoxic concentrations of all 5-FU
formulations exerted concentration-dependent colony-
inhibiting activity compared to control (p < 0.05) (Figure 5).
The 5-FU solution (0.02 μg/mL) had a better colony-
inhibiting activity compared to the SLN formulations.
Among the SLNs, only 5-FU CP SLN (0.12 μg/mL at 24 h
and 0.01 μg/mL at 48 h) had comparable colony inhibition
with that of 5-FU solution. As anticipated, the blankd CP and GMS SLNs compared to 5-FU solution. At the end of 48 h.
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Podophyllotoxin encapsulated in its lipid nanoparticulate
form provided a long-term cancer growth suppression of
293 T and HeLa cells as determined from colony forma-
tion assay [20].
Leighton tube
Leighton tube study was carried to assess the extent of cel-
lular damage such as destruction of the cell wall and release
of cellular content by the 5-FU SLN formulations in com-
parison with the 5-FU solution. The study showed that the
extent of cellular damage caused by 5-FU SLN formulations
were similar to that of 5-FU solution (Figure 6). At the end
of 48 h, drastic morphological damage was observed with
5-FU-loaded CP SLN (0.01 μg/mL) compared to other for-
mulations and drug solution. No morphological changes
were observed with blank formulations. Similar studies car-
ried out on chitosan nanoparticles showed necrotic morph-
ology when it inhibited cell proliferation of MGC803
cells [21].
Conclusions
SLNs prepared using CP and GMS by hot homogenization
method provided high entrapment (86.94% and 78.56%,
respectively). The method employed showed consistent
and reproducible mean particle sizes (172 to 253 nm).
In vitro release studies revealed that the lipid matrix could
retard the release irrespective of the pH, although it was
found to release it faster in acidic conditions. In vitro
antiproliferative studies on B16F10 revealed that the activ-
ity of 5-FU is retained despite being encapsulated in CP/
GMS. The 5-FU encapsulated in CP showed comparable
antimigrational activity, colony inhibition activity, and cy-
topathic as that of 5-FU solution, and the effects of 5-FU
CP SLNs were better than the effects of 5-FU GMS SLNs.
On the basis of these results, it could be concluded that
5-FU-loaded CP SLNs can be considered a promising sys-
tem for in vivo 5-FU delivery. Further studies in murine
metastatic B16F10 melanoma model can provide vital in-
formation on the potency of CP as a potential carrier for
the delivery of 5-FU.
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